Connect with us

Meridia (sibutramine)

Sibutramine (or MERIDIA®) was mainly prescribed to treat obesity.


Class: Anorectic, Serotonin-norepinephrine Reuptake Inhibitor (SNRI),

FDA Approval: 1997

Dosage Forms: 5 mg, 10 mg, 15 mg

Biological Half-life: 1 hour (sibutramine), 14 hours (M1), 16 hours (M2)

Side Effects: Dizziness, blurred vision, dry mouth, nausea, insomnia, constipation, appetite changes, flushing, muscle/joint pain, high blood pressure, tachycardia

Routes of Administration: Oral

Pregnancy Category: C (US)


Twitter Feed

Gene discovery may explain why Lithium doesn't work for all patients

Researchers found insomnia may increase risk of mood disorder in teens #mentalhealth @PittTweet

Can Tylenol provide relief for social media anxiety? #FOMO #socialanxiety #cyberpsychology